PE20180249A1 - Anticuerpos neutralizadores anti-ccl20 - Google Patents

Anticuerpos neutralizadores anti-ccl20

Info

Publication number
PE20180249A1
PE20180249A1 PE2017002493A PE2017002493A PE20180249A1 PE 20180249 A1 PE20180249 A1 PE 20180249A1 PE 2017002493 A PE2017002493 A PE 2017002493A PE 2017002493 A PE2017002493 A PE 2017002493A PE 20180249 A1 PE20180249 A1 PE 20180249A1
Authority
PE
Peru
Prior art keywords
ccl20
cdr3
refers
complementarity determining
determining region
Prior art date
Application number
PE2017002493A
Other languages
English (en)
Inventor
Toshio Imai
James Bradford Kline
Tetsu Kawano
Luigi Grasso
Yoshimasa Sakamoto
Jared Spidel
Miyuki Nishimura
Kenzo Muramoto
Tatsuo Horizoe
Original Assignee
Eisai Randd Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Randd Man Co Ltd filed Critical Eisai Randd Man Co Ltd
Publication of PE20180249A1 publication Critical patent/PE20180249A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)

Abstract

Referido a un anticuerpo monoclonal anti-CCL20 de humano o porcion de union a antigenos del mismo, caracterizado porque: a) una cadena pesada cuya region determinante de la complementariedad 3 (CDR3) comprende la SEC ID NO: 67 o 68 y b) una cadena ligera cuya region determinante de la complementariedad 3 (CDR3) comprende la SEC ID NO: 75. Estos, son anticuerpos humanizados, quimericos y murinos que presentan especificidad de union por el ligando de la quimioquina humana CC 20 (CCL20). Tambien se refiere a una composicion farmaceutica, un acido nucleico, un vector de expresion recombinante, una celula anfitriona y un metodo para hacer un anticuerpo anti-CCL20. Son utiles en aplicaciones terapeuticas, por ejemplo, para tratar los trastornos inflamatorios y autoinmunes, cancer, entre otros.
PE2017002493A 2010-11-19 2011-11-18 Anticuerpos neutralizadores anti-ccl20 PE20180249A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41561410P 2010-11-19 2010-11-19

Publications (1)

Publication Number Publication Date
PE20180249A1 true PE20180249A1 (es) 2018-02-02

Family

ID=46084688

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2013001216A PE20140633A1 (es) 2010-11-19 2011-11-18 Anticuerpos neutralizadores anti-ccl20
PE2017002493A PE20180249A1 (es) 2010-11-19 2011-11-18 Anticuerpos neutralizadores anti-ccl20

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2013001216A PE20140633A1 (es) 2010-11-19 2011-11-18 Anticuerpos neutralizadores anti-ccl20

Country Status (24)

Country Link
US (3) US8491901B2 (es)
EP (1) EP2640744A4 (es)
JP (3) JP5996549B2 (es)
KR (1) KR101919170B1 (es)
CN (1) CN103874707B (es)
AR (1) AR084141A1 (es)
AU (2) AU2011329647B2 (es)
BR (1) BR112013012396A2 (es)
CA (1) CA2818548A1 (es)
CL (1) CL2013001403A1 (es)
CO (1) CO6761352A2 (es)
CR (1) CR20130228A (es)
DO (1) DOP2013000111A (es)
EA (1) EA029419B1 (es)
IL (1) IL226383B (es)
MA (1) MA34738B1 (es)
MX (1) MX361929B (es)
NZ (1) NZ611269A (es)
PE (2) PE20140633A1 (es)
SG (2) SG10201509499RA (es)
TW (1) TWI589587B (es)
UA (1) UA114077C2 (es)
WO (1) WO2012068540A2 (es)
ZA (3) ZA201303571B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ611269A (en) * 2010-11-19 2015-03-27 Eisai R&D Man Co Ltd Neutralizing anti-ccl20 antibodies
WO2013123152A2 (en) 2012-02-17 2013-08-22 Seattle Genetics, Inc. ANTIBODIES TO INTEGRIN αVβ6 AND USE OF SAME TO TREAT CANCER
US20150368329A1 (en) * 2012-10-15 2015-12-24 Oncomed Pharmaceuticals, Inc. Methods of Treating Ocular Diseases
ES2814150T3 (es) * 2014-04-08 2021-03-26 Boston Pharmaceuticals Inc Moléculas de unión específicas para IL-21 y usos de las mismas
JP2017517506A (ja) 2014-05-21 2017-06-29 ファイザー・インコーポレイテッド 癌を処置するための抗ｃｃｒ４抗体および４−１ｂｂアゴニストの併用
MA41480A (fr) * 2014-10-17 2017-12-19 Glenmark Pharmaceuticals Sa Anticorps qui se lient au ccr6 et leurs utilisations
EP3233112A2 (en) * 2014-12-17 2017-10-25 Cancer Research Technology Limited Anti-cxcl12 antibody molecules and their uses
EP3666282A1 (en) 2015-06-03 2020-06-17 The Medical College of Wisconsin, Inc. An engineered ccl20 locked dimer polypeptide
US11571462B2 (en) 2015-06-03 2023-02-07 The Medical College Of Wisconsin, Inc. Engineered CCL20 locked dimer polypeptide
KR20180027568A (ko) * 2015-07-14 2018-03-14 메디뮨 엘엘씨 암을 치료하기 위한 조성물 및 방법
WO2017064564A2 (en) * 2015-10-16 2017-04-20 Glaxosmithkline Intellectual Property Limited Therapeutic regimens for treating psoriatic arthritis with an anti-ccl20 antibody
RU2018130106A (ru) * 2016-01-21 2020-02-21 Дзе Скриппс Рисерч Инститьют Вакцина против синтетических опиоидов
JOP20170013B1 (ar) 2016-01-22 2021-08-17 Merck Sharp & Dohme أجسام xi مضادة لعامل مضاد للتجلط
CN109476758B (zh) 2016-06-14 2023-05-23 默沙东有限责任公司 抗-凝血因子xi抗体
EP3560957A4 (en) * 2016-11-14 2020-10-21 Dinona ANTIBODIES BINDING SPECIFICALLY TO CD66C AND ASSOCIATED USE
FR3072779A1 (fr) * 2017-10-19 2019-04-26 Sinnovial Procede d'estimation de l'efficacite d'un modulateur de la costimulation des lymphocytes t contre la polyarthrite rhumatoide apres reponse inadequate a une biotherapie
WO2019094608A1 (en) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof
EP3706795A4 (en) 2017-11-09 2021-10-13 Pinteon Therapeutics Inc. METHODS AND COMPOSITIONS FOR GENERATING AND USING HUMANIZED CONFORMATION SPECIFIC PHOSPHORYLATED TAU ANTIBODIES
US20220144961A1 (en) * 2019-03-11 2022-05-12 Xyence Therapeutics, Inc. Cd27-binding antibodies and uses thereof
WO2021113697A1 (en) * 2019-12-05 2021-06-10 Seagen Inc. Anti-avb6 antibodies and antibody-drug conjugates
CN113087795A (zh) * 2019-12-23 2021-07-09 上海普铭生物科技有限公司 针对趋化因子cx3cl1的抗体及其应用
WO2023028451A2 (en) * 2021-08-25 2023-03-02 Ibio, Inc. Anti-cd-25 antibody
CN117209603B (zh) * 2021-12-02 2024-02-27 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4897348A (en) 1983-08-25 1990-01-30 Sri International Recombinant materials and methods for producing human connective tissue-activating peptide-III and analogs thereof
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
DE3856559T2 (de) 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
CH681625A5 (es) 1988-12-08 1993-04-30 Sandoz Ag
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5212073A (en) 1989-05-12 1993-05-18 Genetics Institute, Inc. Process for producing human JE cytokine
US5179078A (en) 1989-05-12 1993-01-12 Dana Farber Cancer Institute Method of suppressing tumor formation in vivo
DE69020573T3 (de) 1989-09-25 1999-12-16 Crc Technology Ltd., London Verfahren zur wachstumshemmung von stammzellen.
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
NZ237202A (en) 1990-02-23 1994-01-26 Bristol Myers Squibb Co Composition containing beta-lactam antibiotic and cationic oligopeptide
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
JPH06503710A (ja) 1990-09-14 1994-04-28 カイロン　コーポレイション 酵母細胞におけるマクロファージ誘導タンパク質（ｍｉｐ）の発現
US6001649A (en) 1990-11-29 1999-12-14 Societe Anonyme: Elf Sanofi Chemokine NC28 (monocyte chemotactic protein-3, MCP-3) polypeptides and their recombinant production
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
US5401651A (en) 1991-10-16 1995-03-28 Walz; Alfred DNA encoding ENA-78, a neutrophil activating factor
US5306709A (en) 1991-11-15 1994-04-26 The University Of Pennsylvania Suppression of megakaryocytopoiesis by macrophage inflammatory proteins
US5346686A (en) 1992-10-05 1994-09-13 Mallinckrodt Medical, Inc. Labelled interleukin-8 and medical uses thereof
US5413778A (en) 1992-10-05 1995-05-09 The Regents Of The University Of Michigan Labelled monocyte chemoattractant protein material and medical uses thereof
PT804070E (pt) 1993-03-09 2000-11-30 Genzyme Corp Isolamento de componentes de interesse a partir do leite.
US5474983A (en) 1993-03-15 1995-12-12 The Research Foundation Of State University Of New York Method of inhibiting pro-inflammatory mediator release from basophils and mast cells
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
JPH0789866A (ja) 1993-09-21 1995-04-04 Nippon Kayaku Co Ltd 感染防御剤
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
JP3677288B2 (ja) 1993-12-22 2005-07-27 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド マクロファージ炎症蛋白質−３、−４および−１▲下γ▼
JPH10500301A (ja) 1994-05-16 1998-01-13 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド マクロファージ遊走阻止因子−３
DE69428460T2 (de) 1994-05-16 2002-05-23 Human Genome Sciences, Inc. Chemotaktisches protein
EP1006188B1 (en) 1994-08-23 2006-12-27 Human Genome Sciences, Inc. Human chemokine polypeptides
US6458349B1 (en) 1995-06-02 2002-10-01 Human Genome Sciences, Inc. Chemokine β-4 polypeptides
WO1996005856A1 (en) 1994-08-23 1996-02-29 Human Genome Sciences, Inc. Human chemokine polypeptides
EP0777494B1 (en) 1994-08-23 2004-03-24 Human Genome Sciences, Inc. Human chemokine polypeptides
US6174995B1 (en) 1994-08-23 2001-01-16 Haodong Li Human chemokines, CKβ4 and CKβ10/MCP-4
ES2235172T3 (es) 1994-08-23 2005-07-01 Human Genome Sciences, Inc. Quimioquina humana beta-9.
US5981230A (en) 1994-08-23 1999-11-09 Human Genome Sciences, Inc. Polynucleotide encoding chemokine β-4
WO1996009062A1 (en) 1994-09-23 1996-03-28 University Of Nebraska Board Of Regents Polypeptide agonists and antagonists of human interleukin-8
EP0792278B1 (en) 1994-11-07 2007-06-13 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US5602008A (en) 1994-11-29 1997-02-11 Incyte Pharmaceuticals, Inc. DNA encoding a liver expressed chemokine
US6046037A (en) 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
AU2363695A (en) 1995-04-27 1996-11-18 Human Genome Sciences, Inc. Human tumor necrosis factor receptors
AU723891B2 (en) 1995-06-05 2000-09-07 Human Genome Sciences, Inc. Human chemokine beta-11 and human chemokine alpha-1
WO1996039521A1 (en) 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Human chemokine beta-13
WO1996039520A1 (en) 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Human chemokine beta-12
WO1997015594A1 (en) 1995-10-24 1997-05-01 Smithkline Beecham Corporation Novel chemokine for mobilizing stem cells
ZA968896B (en) 1995-10-24 1997-04-24 Smithkline Beecham Corp Method of mobilizing hematopoietic stem cells
EP0885293B1 (en) 1996-02-23 2006-06-07 Human Genome Sciences, Inc. Human chemokine polypeptides
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
JP2000508527A (ja) 1996-03-27 2000-07-11 アイコス コーポレイション 単球走化性タンパク質―５物質及び方法
US6290948B1 (en) 1996-05-14 2001-09-18 Smithkline Beecham Corporation Method of treating sepsis and ARDS using chamohine beta-10
EP0909321A2 (en) 1996-07-05 1999-04-21 Schering Corporation Mammalian chemokine reagents
KR20010102191A (ko) 1996-08-16 2001-11-15 벤슨 로버트 에이치. 인간의 엔도킨 알파 단백질
DE69738749D1 (de) 1996-08-16 2008-07-17 Schering Corp Zelloberflächen-antigen aus säugetieren und verwandte reagenzien
GB9617923D0 (en) 1996-08-28 1996-10-09 Smithkline Beecham Plc Novel receptor
AU4243097A (en) 1996-09-10 1998-04-02 Schering Corporation Mammalian chemokines, related reagents
WO1998014573A1 (en) 1996-09-30 1998-04-09 The General Hospital Corporation Mcp-4 and mcp-5: novel chemokines
WO1998017800A1 (fr) 1996-10-17 1998-04-30 Shionogi & Co., Ltd. Larc, nouvelle chimiokine cc humaine
BR9612752A (pt) 1996-10-25 2000-01-18 Human Genome Sciences Inc Neutrocina
CA2242384A1 (en) 1996-11-15 1998-05-22 Indiana University Foundation Exodus chemokine materials and methods
US7101987B2 (en) * 1996-11-27 2006-09-05 Schering Corporation CCL27 polypeptides
ATE321855T1 (de) 1997-01-14 2006-04-15 Human Genome Sciences Inc Tumor-nekrose-faktor rezeptor 5
ES2286843T3 (es) 1997-01-14 2007-12-01 Human Genome Sciences, Inc. Receptores 6 alfa y 6 beta del factor de necrosis tumoral.
WO1998032856A1 (en) 1997-01-28 1998-07-30 Human Genome Sciences, Inc. Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l)
DK0970213T3 (da) 1997-03-17 2007-05-21 Human Genome Sciences Inc Dödsdomæneholdig receptor
US6972323B1 (en) * 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
JP2002500509A (ja) 1997-04-30 2002-01-08 エフ．ホフマン−ラ ロシュ アーゲー ラットｓｔ３８．２ケモカイン
AU736549B2 (en) 1997-05-21 2001-08-02 Merck Patent Gesellschaft Mit Beschrankter Haftung Method for the production of non-immunogenic proteins
EP1003767A4 (en) 1997-05-30 2003-01-02 Human Genome Sciences Inc TR10 RECEPTOR OF HUMAN TUMOR NECROSIS FACTOR
CA2295991A1 (en) 1997-06-11 1998-12-17 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr9
WO1999047674A2 (en) 1998-03-18 1999-09-23 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
CA2341029A1 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
DE69934967T2 (de) 1998-12-08 2007-12-06 Biovation Ltd. Verfahren zur verminderung der immunogenität von proteinen
US6645491B1 (en) 1999-02-03 2003-11-11 Schering Corporation Method for treating inflammatory conditions using an antibody to MIP-3α
EP1149113A1 (en) * 1999-02-03 2001-10-31 Schering Corporation Use of agonists or antagonists of mip-3a in therapy
AU778392B2 (en) 2000-03-03 2004-12-02 Cambridge Antibody Technology Limited Human antibodies against eotaxin and their use
US20040197329A1 (en) 2000-10-13 2004-10-07 Yasunori Nakayama Remedies or preventives for rheumatoid arthritis
AU2002234001B2 (en) 2000-12-05 2008-05-01 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
DE60216606T2 (de) 2001-06-07 2007-04-05 Chemocentryx Inc., Mountain View Zellwanderungsassay
US7468253B2 (en) 2001-06-07 2008-12-23 Chemocentryx, Inc. Method for multiple chemokine receptor screening for antagonists using RAM assay
US7442512B2 (en) 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
AU2002357060A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Antibody categorization based on binding characteristics
US7375192B2 (en) 2002-05-01 2008-05-20 Human Genome Sciences, Inc. Antibodies that specifically bind to chemokine beta-4
WO2004066931A2 (en) * 2003-01-24 2004-08-12 Elan Pharmaceuticals Inc. Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
JP4644663B2 (ja) 2003-06-03 2011-03-02 セル ジェネシス インコーポレイテッド ペプチド開裂部位を用いた単一ベクターからの組換えポリペプチドの高められた発現のための構成と方法
CN1898267B (zh) 2003-11-01 2012-05-23 默克专利股份有限公司 修饰的抗cd52抗体
KR20070094890A (ko) 2004-10-25 2007-09-27 머크 앤드 캄파니 인코포레이티드 안티 ａｄｄｌ 항체 및 그 용도
SI1850873T1 (sl) 2005-02-08 2019-05-31 Genzyme Corporation Protitelesa proti TGFBETA
JP2009096716A (ja) * 2006-01-19 2009-05-07 Eisai R & D Management Co Ltd 抗ｃｃｌ２０抗体による自己免疫疾患の治療
EP2217625B1 (en) * 2007-11-08 2021-08-04 Precision Biologics, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
KR101615935B1 (ko) * 2007-12-14 2016-04-28 노보 노르디스크 에이/에스 인간 ｎｋｇ2ｄ에 대한 항체 및 그것의 용도
US20110123542A1 (en) * 2008-06-24 2011-05-26 Hadasit Medical Research Services And Development Ltd. Ccl20-specific antibodies for cancer therapy
EP2352763B2 (en) * 2008-10-01 2022-09-21 Amgen Research (Munich) GmbH Bispecific single chain antibodies with specificity for high molecular weight target antigens
NZ611269A (en) * 2010-11-19 2015-03-27 Eisai R&D Man Co Ltd Neutralizing anti-ccl20 antibodies
WO2013005649A1 (ja) * 2011-07-01 2013-01-10 協和発酵キリン株式会社 抗ヒトｃｃｒ６抗体
JP7089866B2 (ja) 2017-12-22 2022-06-23 セーレン株式会社 開口部を有するシート状物およびその製造方法

Also Published As

Publication number Publication date
AU2011329647B2 (en) 2015-10-22
JP2018042578A (ja) 2018-03-22
ZA201406017B (en) 2017-06-28
DOP2013000111A (es) 2014-06-15
KR20130135872A (ko) 2013-12-11
JP6289520B2 (ja) 2018-03-07
US20140045215A1 (en) 2014-02-13
MA34738B1 (fr) 2013-12-03
NZ611269A (en) 2015-03-27
AU2016200359B2 (en) 2018-05-24
IL226383A0 (en) 2013-07-31
BR112013012396A2 (pt) 2020-11-10
EP2640744A2 (en) 2013-09-25
US9133273B2 (en) 2015-09-15
PE20140633A1 (es) 2014-05-30
KR101919170B1 (ko) 2018-11-15
CN103874707A (zh) 2014-06-18
MX2013005532A (es) 2013-09-26
CO6761352A2 (es) 2013-09-30
US20160046707A1 (en) 2016-02-18
AR084141A1 (es) 2013-04-24
US9809647B2 (en) 2017-11-07
WO2012068540A2 (en) 2012-05-24
AU2016200359A1 (en) 2016-02-11
ZA201701051B (en) 2018-05-30
US8491901B2 (en) 2013-07-23
TW201305204A (zh) 2013-02-01
JP2016093195A (ja) 2016-05-26
CN103874707B (zh) 2017-04-19
EP2640744A4 (en) 2014-05-28
TWI589587B (zh) 2017-07-01
UA114077C2 (xx) 2017-04-25
ZA201303571B (en) 2014-12-23
US20120148592A1 (en) 2012-06-14
IL226383B (en) 2018-07-31
JP2014502154A (ja) 2014-01-30
AU2011329647A1 (en) 2013-05-02
MX361929B (es) 2018-12-19
CL2013001403A1 (es) 2014-08-08
JP5996549B2 (ja) 2016-09-21
WO2012068540A3 (en) 2012-09-27
EA029419B1 (ru) 2018-03-30
SG191716A1 (en) 2013-08-30
SG10201509499RA (en) 2015-12-30
CR20130228A (es) 2013-09-18
CA2818548A1 (en) 2012-05-24
EA201390738A1 (ru) 2013-12-30

Similar Documents

Publication Publication Date Title
PE20180249A1 (es) Anticuerpos neutralizadores anti-ccl20
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
CL2023002239A1 (es) Anticuerpos de b7-h4 y métodos para usarlos
PE20190976A1 (es) Anticuerpos de union a cd3
PH12018501554A1 (en) Ror1 antibody compositions and related methods
PE20221580A1 (es) Anticuerpos terapeuticos y sus usos
AR110676A1 (es) Tratamiento del cáncer utilizando receptores de antígenos quiméricos
AR102698A1 (es) Anticuerpos contra cd73 y sus usos
CY1117922T1 (el) Her2/neu-eiδika αντισωματα και μεθοδοι χρησης αυτων
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
PE20211284A1 (es) Anticuerpos anti-nkg2a y usos de los mismos
BR112017019978A2 (pt) anticorpo ou um fragmento de ligação com antígeno, conjugado, receptor de antígeno, cadeia, conjugado de cadeia, proteína de fusão, célula t, polinucleotídeo, vetor, célula ex vivo, método para produzir uma cadeia, método para produzir um anticorpo, composição farmacêutica, método para tratamento de câncer, glicopeptídeo, método para gerar um anticorpo
FI3389699T3 (fi) Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja
AR096617A1 (es) Anticuerpos anti-tweakr y sus usos
PE20190737A1 (es) Anticuerpos anti-cd27
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
EA201691925A1 (ru) Биспецифические антитела, которые связываются с cd38 и cd3
EA201590208A1 (ru) Усиление активности т-клеток car путем совместного введения биспецифического антитела
PE20121649A1 (es) Anticuerpos monoclonales frente a progastrina y sus usos
PE20141908A1 (es) Anticuerpos cd47 y metodos de uso los mismos
PE20130207A1 (es) Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones
PE20081478A1 (es) Anticuerpos cd44
PE20081625A1 (es) Proteinas de union al antigeno del receptor a de la il-17
PE20091193A1 (es) Proteinas humanas de union a antigenos del gm-csf
MY175878A (en) Anti-il-17 antibodies, a method for producing and using thereof